Extension Study of Ataluren (PTC124) in Cystic Fibrosis

Exclusion Criteria

• •Known hypersensitivity to any of the ingredients or excipients of the study drug (list provided at study sites).
• •Current pregnancy or lactating, or pregnancy or lactating during the previous Phase 3 study.
• •Ongoing participation in any other therapeutic clinical trial.
• •Prior or ongoing medical condition (for example, concomitant illness, psychiatric condition, behavioral disorder, alcoholism, drug abuse), medical history, physical findings, ECG findings, or laboratory abnormality that, in the Investigator's opinion, could adversely affect the safety of the participant, makes it unlikely that the course of treatment or follow up would be completed, or could impair the assessment of study results.